Table 1.
CircMAPK9 expression in the obese sample
| Clinical or molecular feature | CircMAPK9 down-expression (35) | CircMAPK9 over-expression (35) | P |
|---|---|---|---|
| Age (y) | 33 (29, 39) | 30 (26, 40) | 0.445 |
| BMI (kg/m2) | 35.26 ± 4.92 | 41.66 ± 7.28 | < 0.001 |
| HbA1c (%) | 5.9 (5.5, 6.25) | 6 (5.55, 6.55) | 0.441 |
| HOMA-IR | 3.11 (2.21, 4.22) | 4.4 (3.28, 5.69) | 0.004 |
| TC (mmol/L) | 4.46 (4.06, 5.4) | 4.64 (4.29, 5.37) | 0.356 |
| TG (mmol/L) | 1.24 (0.86, 1.96) | 1.81 (1.36, 3) | 0.018 |
| LDL-C (mmol/L) | 2.52 (2.33, 3.41) | 3.11 (2.71, 3.45) | 0.096 |
| HDL-C (mmol/L) | 1.19 (1.02, 1.36) | 1.06 (0.96, 1.24) | 0.055 |
| Hypertension | 51% (18/35) | 57% (20/35) | 0.810 |
| Type Ⅱ Diabetes | 34% (12/35) | 66%(23/35) | 0.017 |
| Hyperlipemia | 34% (12/35) | 51% (18/35) | 0.227 |
| Hyperuricemia | 17% (6/35) | 49% (17/35) | 0.011 |
| OSAS | 23% (8/35) | 29% (10/35) | 0.784 |
| NAFLD | 60% (21/35) | 91% (32/35) | 0.005 |
| Cholelithiasis | 6% (2/35) | 9% (3/35) | 1.000 |
BMI, Body mass index; HbA1c, Glycated hemoglobin; HOMA-IR, Homeostasis model assessment of insulin resistance; TC, Total cholesterol; TG, Triglycerides; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol; OSAS, Obstructive sleep apnea syndrome; NAFLD, Non-alcoholic fatty liver disease.